How to read a peptide study without deceiving yourself: preclinical versus animal versus human trials

Greetings. In my clinical practice in Paris and across telemed consultations, I regularly see active men on TRT or recovery stacks bring me study abstracts for BPC-157, TB-500, and GHK-Cu. Many expect that pinning these compounds will instantly fix years of tendon wear. I want to share how I evaluate these papers when helping guys structure their rehab and protocols. First, looking at in vitro paper mechanisms is useful for understanding how a compound might target fibroblasts, but a cell culture lacks blood flow, mechanical stress, and systemic metabolism. Rodent papers give us great targets for half life and dosing ideas, but researchers typically test acute cuts on young animals. That is vastly different from a lifter dealing with chronic tendinopathy and degenerated collagen after years of heavy load. Here in Europe, our prescribing norms and access to compounding differ from the US, but the biological fundamentals are identical. If you choose to run BPC or TB sub-q alongside your routine, view them as adjuncts that assist the process, not magic erasers. You still need structured PT, progressive mechanical loading, adequate protein, and quality sleep to actually rebuild tissue.